Boston Scientific Corporation (NYSE:BSX) acquired Obsidio, Inc. on August 15, 2022. The transaction is expected to be immaterial to Boston Scientific's GAAP and adjusted earnings per share in 2022. Wilson Sonsini Goodrich & Rosati, P.C. acted as legal advisor to Obsidio, Inc. Julie Scallen of Latham & Watkins provided legal counsel to Boston Scientific Corporation.

Boston Scientific Corporation completed the acquisition of Obsidio, Inc. on August 15, 2022. During the first nine months of 2022, cash used for investing activities included net cash payments of $1.542 billion for the acquisitions of Baylis Medical and Obsidio, Inc, as well as purchases of property, plant and equipment and internal use software of $376 million.